MEK Inhibitors Enhance post-radiation anti-tumor Immunity in KRAS-Mutant Lung Cancer
RNA-seq (gene expression) · mouse · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 12 samples: 3 × Control vs 3 × MEKi vs 3 × RT vs 3 × MEKi+RTGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancerFrontiers in immunology · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE297753_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1266119 and SRA study SRP586817. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8998922 Control rep1 Control
- GSM8998923 Control rep2 Control
- GSM8998924 Control rep3 Control
- GSM8998925 MEKi rep1 MEKi
- GSM8998926 MEKi rep2 MEKi
- GSM8998927 MEKi rep3 MEKi
- GSM8998928 RT rep1 RT
- GSM8998929 RT rep2 RT
- GSM8998930 RT rep3 RT
- GSM8998931 MEKi+RT rep1 MEKi+RT
- GSM8998932 MEKi+RT rep2 MEKi+RT
- GSM8998933 MEKi+RT rep3 MEKi+RT
- GSE64102 Improved antitumor activity of immunotherapy combined with BRAF and MEK inhibitors in BRAFV600E mutant melanoma 13 samples shares mek, inhibitors
- GSE276571 MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors 26 samples shares inhibitors, enhance
- GSE295646 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in acute myeloid leukaemia [mouse RNA-seq] 20 samples shares inhibitors, enhance
- GSE304654 Engineered miR-122 inhibitors enhance endothelial mitochondrial efficiency and improve vascular function 16 samples shares inhibitors, enhance
- GSE236258 Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation 15 samples shares kras-mutant, lung
- GSE309596 Combination of PARP and KRASG12D Inhibitors Enhances Therapeutic Efficacy by Exploiting Vulnerabilities(scRNA) 12 samples shares inhibitors, enhance
- GSE308031 Engineered Nanobodies Targeting Endogenous Digoxin-like Substances Function as Novel Immune Checkpoints Inhibitors and Enhance Immunotherapy against Cancer Metastasis 12 samples shares inhibitors, enhance
- GSE308027 Engineered Nanobodies Targeting Endogenous Digoxin-like Substances Function as Novel Immune Checkpoints Inhibitors and Enhance Immunotherapy against Cancer Metastasis 9 samples shares inhibitors, enhance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.